Building a Business Case for Biopharmaceutical QbD Implementation (Peer Reviewed) - The author describes a methodology for developing a per product qualitative and semi-qualitative business case for a

ADVERTISEMENT

Building a Business Case for Biopharmaceutical QbD Implementation (Peer Reviewed)
The author describes a methodology for developing a per product qualitative and semi-qualitative business case for applying QbD to a biopharmaceutical product.


BioPharm International
Volume 25, Issue 8, pp. 40-47

REFERENCES

1. T. Fuhr, M. Holcomb, and P. Rutten, "Why Quality-by-Design Should be on the Executive Team's Agenda: Developing New Strategies for New Times," in Outpacing Change in Pharma Operations, M. Losch, and U. Schrader, Eds. (McKinsey & Co., December, 2009) pp. 195–203.

2. B. Schmidt, "Implementing Quality by Design: Are you ready, or not?" Aug. 4, 2010, http://www.pharmaqbd.com/schmidt_ready_for_qbd/, accessed Jul. 17, 2012.

3. H. Winkle, "Regulatory Modernization- FDA's Desired State for Product Quality," presentation at the BioProcess International Conference (Providence, RI, Sept. 21, 2010).

4. H.N. Winkle and M.M. Nasr, Pharm. Tech. Eur. 23 (9), 10–19 (2011).

5. H.L. Levine, S.D. Jones, and A.D. Kanarek, Bioprocess Int. 9 (1), 64 (2011).

6. FDA, "Advancing Regulatory Science at FDA. A Strategic Plan," Aug. 2011, p. 14. http://www.fda.gov/regulatoryscience, accessed Jul. 17, 2012.

7. T. Agres, Drug Disc. Devel. 14 (3), 10–11 (2011).

8. ICH Q8R2, Pharmaceutical Development, (August 2009).

9. J. Woodcock, "Pharmaceutical GMP's for the 21st Century: FDA's New Initiative on Drug Product Quality," Oct. 29, 2002, http://www.fda.gov/ohrms/dockets/ac/02/slides/3902s1-11-Woodcock.ppt, accessed Jul. 17, 2012.

10. M. Welin, EU Regulatory Feedback, presentation at ISPE meeting (Brussels, Sept. 2010).

11. J.A.C. Lim et al., Bioprocess Int. 8 (10), 62–70 (2010).

12. B. Junker, BioPharm Int. 22 (5), 40–50 (2009).

13. C. Woelbeling, Pharmaceutical Engineering 28 (3), 36–48 (2008).

14. B. Chatterjee, Pharmaceutical Processing 26 (4), 8–9 (2011).

15. E. David, T. Tramontin, and R. Zemmel, Nat. Rev. Drug Disc. 8, 609–610 (2009).

16. E. David, T. Tramontin, and R. Zemmel, R., The Road to Positive R&D Returns, http://www.mckinseyquarterly.com/Health_Care/Pharmaceuticals/The_road_to_positive_.../. 2010, accessed Jul. 17, 2012.

17. Z. Shahrokh, S. Price, and M. Voloch, BioPharm Int. 24 (8), 35–43 (2011).

18. S.D. Jones, and H.L. Levine, "Integrating Quality by Design into Early Process Development," presentation at IBC Preclinical Scale Bioprocessing Conference (Boston, MA, Nov. 1–3, 2010).

19. Center for Chemical Process Safety, The Business Case for Process Safety, (American Institute of Chemical Engineers, 2nd Ed, 2010).

20. S. Martin-Moe et al., J. Pharm. Sci. 100 (8), 3031–3043 (2011).


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Bristol-Myers Squibb and Five Prime Therapeutics Collaborate on Development of Immunomodulator
November 26, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
Author Guidelines
Source: BioPharm International,
Click here